These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2993436)

  • 1. Cytomegalovirus vaccine virus (Towne strain) does not induce latency.
    Plotkin SA; Huang ES
    J Infect Dis; 1985 Aug; 152(2):395-7. PubMed ID: 2993436
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of cytomegalovirus disease by Towne strain live attenuated vaccine.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Birth Defects Orig Artic Ser; 1984; 20(1):271-87. PubMed ID: 6329367
    [No Abstract]   [Full Text] [Related]  

  • 3. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants.
    Plotkin SA; Smiley ML; Friedman HM; Starr SE; Fleisher GR; Wlodaver C; Dafoe DC; Friedman AD; Grossman RA; Barker CF
    Lancet; 1984 Mar; 1(8376):528-30. PubMed ID: 6142252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
    Plotkin SA; Higgins R; Kurtz JB; Morris PJ; Campbell DA; Shope TC; Spector SA; Dankner WM
    Transplantation; 1994 Dec; 58(11):1176-8. PubMed ID: 7992358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for the prevention of human cytomegalovirus infection.
    Plotkin SA; Starr SE; Friedman HM; Gonczol E; Brayman K
    Rev Infect Dis; 1990; 12 Suppl 7():S827-38. PubMed ID: 2173112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress toward developing a cytomegalovirus vaccine.
    Marshall GS; Plotkin SA
    Infect Dis Clin North Am; 1990 Jun; 4(2):283-98. PubMed ID: 2161034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus vaccine in renal transplant candidates: progress report of a randomized, placebo-controlled, double-blind trial.
    Balfour HH; Sachs GW; Welo P; Gehrz RC; Simmons RL; Najarian JS
    Birth Defects Orig Artic Ser; 1984; 20(1):289-304. PubMed ID: 6329368
    [No Abstract]   [Full Text] [Related]  

  • 9. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial.
    Glazer JP; Friedman HM; Grossman RA; Starr SE; Barker CF; Perloff LJ; Huang ES; Plotkin SA
    Ann Intern Med; 1979 Nov; 91(5):676-83. PubMed ID: 227299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
    Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
    J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
    Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
    J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus vaccine in renal transplants.
    Betts RF
    Ann Intern Med; 1979 Nov; 91(5):780-2. PubMed ID: 227302
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and laboratory studies of live cytomegalovirus vaccine Ad-169.
    Neff BJ; Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1979 Jan; 160(1):32-7. PubMed ID: 217022
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus.
    Quinnan GV; Delery M; Rook AH; Frederick WR; Epstein JS; Manischewitz JF; Jackson L; Ramsey KM; Mittal K; Plotkin SA
    Ann Intern Med; 1984 Oct; 101(4):478-83. PubMed ID: 6089634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
    Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
    J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should renal-transplant patients be screened for C.M.V.?
    Lancet; 1978 Oct; 2(8093):770-1. PubMed ID: 80691
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination against human cytomegalovirus with live virus.
    Plotkin SA; Friedman HM; Starr S; Fleisher G
    Dev Biol Stand; 1982; 52():373-9. PubMed ID: 6299846
    [No Abstract]   [Full Text] [Related]  

  • 20. Vaccination of pediatric nurses with live attenuated cytomegalovirus.
    Fleisher GR; Starr SE; Friedman HM; Plotkin SA
    Am J Dis Child; 1982 Apr; 136(4):294-6. PubMed ID: 6280490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.